References
- Merck to acquire Peloton Therapeutics, bolstering oncology pipeline. https://investors.merck.com/news/press-release-details/2019/Merck-to-Acquire-Peloton-Therapeutics-Bolstering-Oncology-Pipeline/default.aspx
- Peloton Therapeutics website. www.pelotontherapeutics.com/
- Mishra M . (Reuters). Merck buys Peloton to expand its kidney cancer treatment portfolio. www.reuters.com/article/us-merck-co-deals/merck-buys-peloton-to-expand-its-kidney-cancer-treatment-portfolioidUSKCN1SR136
- Nektar announces the launch of Inheris Biopharma, Inc. https://ir.nektar.com/news-releases/news-release-details/nektar-announces-launch-inheris-biopharma-inc
- Nektar Therapeutics website. www.nektar.com
- Vertex and Kymera Therapeutics establish strategic collaboration to discover and develop targeted protein degradation medicines for serious diseases. https://investors.vrtx.com/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration
- Kymera Therapeutics website. https://www.kymeratx.com/
- Gong B , RadulovicM , Figueiredo-PereiraME , CardozoC. The ubiquitin-proteasome system: potential therapeutic targets for Alzheimer's disease and spinal cord injury. Front. Mol. Neurosci.9(4), (2016).
- Parvus Therapeutics enters into worldwide collaboration and license agreement with Genentech to develop Navacim™ Therapeutics for the treatment of autoimmune diseases. https://parvustx.com/parvus-therapeutics-enters-into-worldwide-collaboration-and-license-agreement-with-genentech-to-develop-navacim-therapeutics-for-the-treatment-of-autoimmune-diseases/
- Parvus Therapeutics website. https://parvustx.com/about/
- Lilly announces licensing agreement for non-opioid pain asset from Centrexion Therapeutics. https://centrexion.com/wp-content/uploads/2019/05/Centrexion_Lilly_Press-Release-5.28.19.pdf
- Centrexion Therapeutics Corporation website. https://centrexion.com/company/#overview
- Somvanshi RK , KumarU. δ-opioid receptor and somatostatin receptor-4 heterodimerization: Possible implications in modulation of pain associated signaling. PLoS ONE9(1), (2014).
- Shenoy PA , KuoA , KhanNet al. The somatostatin receptor-4 agonist J-2156 alleviates mechanical hypersensitivity in a rat model of breast cancer induced bone pain. Front. Pharmacol.9, 495 (2018).
- Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists. www.gubra.dk/about-us/press-releases/boehringer-ingelheim-and-gubra-announce-new-collaboration-to-develop-anti-obesity-peptide-poly-agonists/
- Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments. www.gubra.dk/about-us/press-releases/boehringer-ingelheim-and-gubra-collaborate-to-develop-next-generation-obesity-treatments/
- Gubra website. www.gubra.dk/
- DelSiTech Ltd receives significant funding for developing long-acting injectables. www.prnewswire.com/news-releases/delsitech-ltd-receives-significant-funding-for-developing-long-acting-injectables-300853314.html
- DelSiTech website. http://www.delsitech.com/
- Lilly's CYRAMZA® (ramucirumab) becomes first FDA-approved biomarker-driven therapy in patients with hepatocellular carcinoma. http://lilly.mediaroom.com/index.php?s=9042&item=137901
- Entry for Cyramza on Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477lbl.pdf
- Helfland C . Lilly's Cyramza scores in targeted lung cancer—but major competition awaits. https://www.fiercepharma.com/pharma/eli-lilly-s-cyramza-scores-a-win-targeted-lung-cancer-but-major-competition-awaits
- FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease
- AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA). http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2399684
- AveXis, Inc website. www.avexis.com/about
- $2.1m Novartis gene therapy to become world's most expensive drug. The Guardian. www.theguardian.com/science/2019/may/25/21m-novartis-gene-therapy-to-become-worlds-most-expensive-drug
- Tocagen's Toca 5 pivotal phase III clinical trial in patients with recurrent brain cancer continues without modification at planned interim analysis. http://ir.tocagen.com/news-releases/news-release-details/tocagens-toca-5-pivotal-phase-3-clinical-tr
- Tocagen website. https://tocagen.com/about-us/
- BioMarin announces that Phase III cohort of Valoctocogene Roxaparvovec, gene therapy study in severe hemophilia A met pre-specified criteria for regulatory submissions in the U.S. and Europe. https://investors.biomarin.com/2019-05-28-BioMarin-Announces-that-Phase-3-Cohort-of-Valoctocogene-Roxaparvovec-Gene-Therapy-Study-in-Severe-Hemophilia-A-Met-Pre-Specified-Criteria-for-Regulatory-Submissions-in-the-U-S-and-Europe
- Biomarin website. www.biomarin.com/
- HedgePath Pharmaceuticals announces notice of allowability of U.S. Patent application regarding treatment of prostate cancer. www.prnewswire.com/news-releases/hedgepath-pharmaceuticals-announces-notice-of-allowability-of-us-patent-application-regarding-treatment-of-prostate-cancer-300843692.html
- HedgePath Pharmaceuticals announces notice of allowance with additional claims governing the use of SUBA®Itraconazole for the Treatment of Lung Cancer. https://docs.wixstatic.com/ugd/041d82_59dfa13c8027422b94c635c703d6424b.pdf
- Mayne Pharma website. www.maynepharma.com/
- HedgePath Pharmaceuticals website. www.hedgepathpharma.com/
- BlueWillow Biologics announces issuance of intranasal anthrax vaccine patent. www.bluewillow.com/bluewillow-biologics-announces-issuance-of-intranasal-anthrax-vaccine-patent/
- Blue Willow Biologics website. www.bluewillow.com/
- US Patent 10138279. patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=10138279.PN.&OS=PN/10138279&RS=PN/10138279